Diagnostics
-
Philips to acquire SpectraWAVE
SpectraWAVE makes technologies to help diagnose and guide treatment decisions for coronary artery disease.
By Elise Reuter • Dec. 15, 2025 -
Natera acquires Foresight Diagnostics for up to $450M
Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in 2026.
By Susan Kelly • Dec. 10, 2025 -
Explore the Trendline➔
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
GE HealthCare, Mayo Clinic expand partnership around radiology research
Ben Newton, GE HealthCare’s global head of oncology, said the partnership will shift radiation therapy from a “one-size-fits-all” approach to a personalized method.
By Elise Reuter • Dec. 9, 2025 -
Freenome inks deals to list stock and raise $330M
The company plans to use the proceeds to expand its commercial and data infrastructure to support the launch of multiple blood-based cancer detection tests.
By Nick Paul Taylor • Dec. 8, 2025 -
CHS sells lab assets to Labcorp for $194M
The deal, first announced in July, includes outreach laboratory services in 13 states. CHS will continue to operate inpatient and emergency department labs.
By Susanna Vogel • Dec. 4, 2025 -
PitchBook: AI tuck-in deals to drive M&A acceleration in 2026
Buyers will focus on “tuck-ins that add AI or data-driven capabilities or can meaningfully improve scale against emerging competitors,” the analysts said.
By Nick Paul Taylor • Dec. 3, 2025 -
Cleveland Diagnostics wins FDA nod for prostate cancer test
The IsoPSA test is intended to help assess whether patients with elevated PSA levels should go on to receive a biopsy procedure.
By Susan Kelly • Dec. 2, 2025 -
Abbott’s $21B Exact Sciences buy reveals future strategy
The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.
By Elise Reuter • Nov. 21, 2025 -
Roche inks deal for rights to Freenome cancer tests outside US
Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits, similar to with their prior success in IVD kits.”
By Nick Paul Taylor • Nov. 20, 2025 -
Abbott to acquire Exact Sciences for about $21B
The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.
By Elise Reuter , Susan Kelly • Updated Nov. 20, 2025 -
Labcorp inks deal to buy Parkview Health outreach laboratory assets
The takeover extends a string of deals that have consolidated the outreach lab services market.
By Nick Paul Taylor • Nov. 14, 2025 -
Siemens to reduce stake in Siemens Healthineers
Siemens Healthineers CEO Bernd Montag said the decision is a “natural next step in our journey to becoming a fully independent company.”
By Susan Kelly • Nov. 13, 2025 -
Retrieved from Olympus on February 03, 2025
Olympus to cut 2,000 jobs in endoscopy reorganization
The workforce reduction is part of a restructuring designed to improve accountability and accelerate growth and innovation.
By Susan Kelly • Nov. 7, 2025 -
Health groups urge passage of bill to ease Medicare pay cuts for tests
More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.
By Susan Kelly • Nov. 3, 2025 -
Sponsored by Danaher
Turning aspirational innovations into tangible impacts
Making tomorrow’s breakthroughs a reality for the patients who need.
Nov. 3, 2025 -
Agilent selects Adam Elinoff as CFO
The appointment fills a position made available when Bob McMahon resigned as CFO on July 31.
By Nick Paul Taylor • Oct. 31, 2025 -
Profile
Hemorrhage can be a serious problem after pregnancy. Here’s how one medtech founder is tackling it
Kelsey Mayo, CEO of Armor Medical, received the grand prize in MedTech Innovator’s pitch competition for a wearable technology to detect serious blood loss early.
By Elise Reuter • Oct. 23, 2025 -
Hologic to go private for up to $18.3B
Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.
By Elise Reuter • Oct. 21, 2025 -
AdvaMed calls for series of trade actions in response to Section 232 probe
In comments submitted to the Trump administration on its medical equipment investigation, the industry group recommended a tariff-free trading bloc with trusted countries among its proposals.
By Susan Kelly • Oct. 20, 2025 -
BD CFO Chris DelOrefice leaving for new job
Along with DelOrefice’s departure, BD reported preliminary fiscal fourth-quarter revenue that analysts said was below Wall Street consensus expectations.
By Susan Kelly • Oct. 16, 2025 -
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout
The Sanofi partnership will support clinical validation and regulatory submissions for Revvity’s new assay. Elsewhere, Kihealth raised $5 million in seed funding to launch its early detection test.
By Susan Kelly • Oct. 6, 2025 -
CDRH shares regulatory guidance priorities for the coming 12 months
Use of real-world evidence to support regulatory decisions and predetermined change control plans for medical devices are two areas of focus for the agency.
By Nick Paul Taylor • Oct. 2, 2025 -
MedTech Europe pressures EU to make regulatory changes by early 2026
The request includes a call to postpone re-certification requirements for devices already certified under the medical technology regulations.
By Nick Paul Taylor • Sept. 26, 2025 -
Quest to distribute Guardant colon cancer blood test
Guardant Health Co-CEO AmirAli Talasaz also unveiled plans to launch the Shield test for multi-cancer detection in October.
By Susan Kelly • Sept. 25, 2025 -
Multi-cancer blood tests aren’t ready for routine use, review says
Research funded by the Agency for Healthcare Research and Quality found insufficient evidence to determine the accuracy — or possible harm — of the cancer screenings.
By Susan Kelly • Sept. 23, 2025